Anne VanLent Appointed to Aegerion Pharmaceuticals' Board of Directors

Anne VanLent Appointed to Aegerion Pharmaceuticals' Board of Directors

CAMBRIDGE, Mass., April 29, 2013 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals,
Inc. (Nasdaq:AEGR), a biopharmaceutical company dedicated to the development
and commercialization of innovative, life-altering therapies for patients with
debilitating, often fatal, rare diseases, today announced the appointment of
Anne M. VanLent to its Board of Directors, effective April 26, 2013. Ms.
VanLent will serve as Chair of the Audit Committee.

Ms. VanLent is currently the President of AMV Advisors, an advisory firm which
she founded in 2008 to provide corporate strategy and financial consulting
services to emerging growth life science companies. Previously, Ms. VanLent
was Executive Vice President and Chief Financial Officer of Barrier
Therapeutics, Inc. Prior to that, she was Executive Vice President, Portfolio
Management for Sarnoff Corporation, a multidisciplinary research and
development firm. Earlier in her career, she served as Senior Vice President
and Chief Financial Officer of The Liposome Company, Inc. Ms. VanLent also
currently serves as a member of the Board of Directors of Integra LifeSciences
and Tranzyme Pharma, where she serves as Audit Chair. She has previously
served as a member of the Board of Directors of Penwest Pharmaceuticals and
i-STAT Corporation.

"Anne brings industry experience, strategic corporate leadership and deep
financial knowledge to our Board at a pivotal time for the company," said
David Scheer, Chairman of the Board.

Marc D. Beer, Chief Executive Officer of Aegerion, added, "We welcome Anne as
a valued addition to our Board as we seek to become a leading biotechnology
company focused on developing and commercializing therapies for rare diseases.
Anne's guidance will be invaluable through these early days of commercial
launch and beyond."

Anne VanLent also added, "Aegerion has established a best-in-class Board and I
am pleased to have the opportunity to contribute to the company's growth and
ongoing success in a meaningful way. I am excited to be a part of a
patient-centric organization which has begun the journey of helping people
with HoFH."

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the
development and commercialization of innovative, life-altering therapies for
patients with debilitating, often fatal, rare diseases. For more information
about the company, please visit www.aegerion.com.

CONTACT: Aegerion Pharmaceuticals, Inc.
         Amanda Murphy
         Manager, Investor Relations
         (857) 242-5024

Aegerion Pharmaceuticals, Inc. Logo
 
Press spacebar to pause and continue. Press esc to stop.